D3 Selective Dopamine Antagonist Compound Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds targeting the dopamine D3 receptor lack high D3/D2 selectivity, leading to undesirable side effects and limited efficacy in treating associated diseases.
Innovation Solution
Development of a compound represented by Formula (I), which includes specific aromatic heterocycles and carbocycles, offering high D3/D2 selectivity and antagonistic activity for the dopamine D3 receptor, thereby reducing side effects and enhancing therapeutic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds with D3 receptor affinity are used, then therapeutic potential for D3-associated diseases is achieved, but D3/D2 selectivity is insufficient leading to side effects
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions on the aromatic ring system. The substituents R1-R6 are strategically placed to create localized electronic and steric properties that enhance D3 receptor binding while maintaining D2 selectivity, resolving the contradiction between therapeutic potential and side effect profile
Solution Approach 2:
The patent employs parameter changes by systematically varying substituent types (halogen, alkyl, alkoxy, nitro, cyano groups) and their positions on the aromatic core structure. These chemical parameter modifications tune the receptor binding characteristics to achieve high D3/D2 selectivity ratio, directly addressing the selectivity-side effect contradiction
2Adaptability or versatility
If D2 receptor antagonists are used to treat D3-associated diseases, then broad dopamine receptor coverage is achieved, but extrapyramidal side effects occur
Solution Approach 1:
The patent applies segmentation by designing a molecular structure that selectively targets D3 receptor subtype while excluding D2 receptor interaction. The specific aromatic heterocyclic core with defined substituent patterns creates a binding profile segmented for D3 selectivity, eliminating extrapyramidal side effects while maintaining therapeutic efficacy for D3-associated disorders
3Reliability
If compounds with high D3 affinity are developed, then therapeutic efficacy for D3 diseases is improved, but structural complexity increases
Solution Approach 1:
The patent applies composite materials principle by constructing the molecule from well-defined modular components: a core aromatic heterocyclic structure (Formula I) combined with specific substituent groups. This composite approach achieves high D3 affinity and therapeutic efficacy while maintaining reasonable structural complexity through systematic assembly of known pharmacophoric elements
Data Source
AI summary
Novel compounds having a D3 receptor antagonistic activity are provided.The compound represented by Formula (I):wherein Ring A is a non-aromatic heterocycle or the like substituted with substituted or unsubstituted aromatic heterocyclyl or the like; R2a to R2d are each independently a hydrogen atom or the like; n is an integer of 0 to 3; Ring B is a non-aromatic carbocycle or the like; R3 is each independently halogen or the like; r is an integer of 0 to 4; -L- is —N(R10)—C(═O), or the like; R10 is a hydrogen atom or the like; R4 is substituted or unsubstituted aromatic heterocyclyl or the like,or a pharmaceutically acceptable salt thereof.